Accro Bioscience closed a $50 million Series C financing round to advance an oral immune-mediated disease pipeline, according to the provided report. The round was led by OrbiMed with participation from TCG Crossover, LAV, Cenova Capital, and other investors. The company described its strategy as focused on delivering oral treatments for patients living with immune-mediated conditions. Accro’s statement highlighted the importance of building a pipeline that targets patients across immune-driven disease needs. The financing underscores investor appetite for oral programs in immune-mediated biology, where convenience and long-term adherence can be decisive for clinical uptake if efficacy and safety are demonstrated.